ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)

31.96
Delayed Data
As of Mar 27
 +1.59 / +5.24%
Today’s Change
15.64
Today|||52-Week Range
46.48
+0.66%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$3.2B

Company Description

ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is developing a portfolio consisting of four advanced product candidates, including pimavanserin, which is in Phase III development for the treatment of Parkinson's disease psychosis. It also has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma. ACADIA Pharmaceuticals was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Contact Information

ACADIA Pharmaceuticals, Inc.
11085 Torreyana Road
San Diego California 92121-1104
P:(858) 558-2871
Investor Relations:

Employees

Shareholders

Other institutional50.44%
Mutual fund holders46.68%
Individual stakeholders29.76%

Top Executives

Stephen R. DavisCEO, CFO, Chief Business Officer & Executive VP
Roger M. MillsChief Medical Officer & Executive VP-Development
Glenn F. BaitySecretary, Executive VP & General Counsel
Terrence O. MooreChief Commercial Officer & Executive VP
Lisa BarthelemyDirector-Investor Relations

To view my watchlist

Not a member yet?

Sign up now for a free account